Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 4/20 | 0.56 |
| ▸ | ABL1 | P00519 | 2/20 | 0.48 |
| ▸ | AAK1 | Q2M2I8 | 7/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | IGF1R | P08069 | 4/20 | 0.39 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.38 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3488848 | 0.93 | MAP4K1 (0.56) | MAP4K1ABL1AAK1CYP3A4IGF1R | |
| SCHEMBL12344647 | 0.91 | MAP4K1 (0.53) | MAP4K1ABL1AAK1CYP3A4IGF1R | |
| SCHEMBL3491862 | 0.90 | MAP4K1 (0.53) | MAP4K1ABL1AAK1CYP3A4IGF1R | |
| SCHEMBL12343707 | 0.90 | MAP4K1 (0.49) | MAP4K1ABL1AAK1CYP3A4IGF1R | |
| SCHEMBL12343429 | 0.89 | MAP4K1 (0.52) | MAP4K1ABL1AAK1CYP3A4IGF1R | |
| SCHEMBL12344646 | 0.89 | MAP4K1 (0.52) | MAP4K1ABL1AAK1CYP3A4IGF1R | |
| SCHEMBL12343425 | 0.89 | MAP4K1 (0.54) | MAP4K1ABL1AAK1CYP3A4IGF1R | |
| SCHEMBL12343426 | 0.89 | MAP4K1 (0.54) | MAP4K1ABL1AAK1CYP3A4IGF1R | |
| SCHEMBL12344671 | 0.89 | MAP4K1 (0.51) | MAP4K1ABL1AAK1CYP3A4IGF1R | |
| SCHEMBL12343493 | 0.89 | MAP4K1 (0.51) | MAP4K1ABL1AAK1CYP3A4IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268994-B2 | Fused ring heterocycle kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268994-B2 | Fused ring heterocycle kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268994-B2 | Fused ring heterocycle kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20100036118-A1 | Fused Ring Heterocycle Kinase Modulators | SGX PHARMACEUTICALS, INC. | 2010-02-11 | — | — | US | disclosed |
| US-20100036118-A1 | Fused Ring Heterocycle Kinase Modulators | SGX PHARMACEUTICALS, INC. | 2010-02-11 | — | — | US | disclosed |
| US-20100036118-A1 | Fused Ring Heterocycle Kinase Modulators | SGX PHARMACEUTICALS, INC. | 2010-02-11 | — | — | US | disclosed |
| EP-2134179-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX Pharmaceuticals, Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| US-7626021-B2 | Fused ring heterocycle kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-7626021-B2 | Fused ring heterocycle kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-7626021-B2 | Fused ring heterocycle kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2009-12-01 | — | — | US | disclosed |
| WO-2008124850-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| US-20070287711-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2007-12-13 | — | — | US | disclosed |
| US-20070287711-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2007-12-13 | — | — | US | disclosed |
| US-20070287711-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287711-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | MAP3K20, TTK, MAP3K19 | MAP4K1 19/4885ABL1 141/4885AAK1 187/4885 |
| US-20100036118-A1 | Fused Ring Heterocycle Kinase Modulators | MAP3K20, TTK, MAP3K19 | MAP4K1 19/4885ABL1 141/4885AAK1 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.